The Limited Times

Now you can see non-English news...

Coronavirus: no convincing efficacy of hydroxychloroquine

2020-05-08T00:15:03.237Z



The administration of hydroxychloroquine, a drug against malaria, did not improve or significantly deteriorate the condition of seriously ill patients with coronavirus, according to a study published Thursday and carried out in New York hospitals. "The risk of intubation or death was not significantly greater or less among patients who received hydroxychloroquine than among those who received nothing , " said the study authors published in the New England Journal. of Medicine .

Funded by the American Institutes of Health (NIH), the observational study was conducted on Covid-19 patients admitted to the emergency departments of New York-Presbyterian Hospital and Columbia University Irving Medical Center. 811 patients received two doses of 600 mg of hydroxychloroquine on the first day and then 400 mg daily for four days. 565 patients did not receive the drug.

Read also: Coronavirus: storming, hydroxychloroquine is missing in lupus patients

The study "should not be used to rule out" the potential benefits or risks that treatment with hydroxychloroquine can bring, scientists say. "However, our results do not support the use of hydroxychloroquine for the moment, apart from randomized clinical trials (distributing patients by lot, Editor's note) to demonstrate its effectiveness," they added.

Donald Trump has regularly advocated the use of hydroxychloroquine as a treatment for patients with coronavirus. Hydroxychloroquine and chloroquine have been used for years to treat malaria, certain autoimmune diseases, such as lupus, and rheumatoid arthritis. Canadian and American health authorities warned, however, in late April against the use outside of supervised clinical trials of these two antimalarials to prevent infection or treat the new coronavirus.

Read also: Should we believe Professor Raoult?

The American Medicines Agency (FDA) also last week urgently authorized the use of the experimental antiviral remdesivir. A large American trial concluded that it shortened the recovery of the most severely Covid-19 patients by several days.

Source: lefigaro

All news articles on 2020-05-08

You may like

Life/Entertain 2024-02-13T16:50:10.975Z

Trends 24h

News/Politics 2024-03-28T06:04:53.137Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.